PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$61.07

05 Dec
2022

0.100

OPEN

$61.40

0.16%

HIGH

$61.80

71,224

LOW

$60.57

TARGET
$56.59 -7.3% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx 42.6 51.6 xxx
DPS (cps) xxx 22.0 24.6 xxx
EPS Growth xxx 43.8% 21.1% xxx
DPS Growth xxx 46.7% 11.6% xxx
PE Ratio xxx N/A 117.1 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 51.6% 47.6% xxx

Dividend yield today if purchased 3 years ago: 0.95%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.36

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - ex-div 12c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx42.6
DPS All xxxxxxxxxxxxxxx22.0
Sales/Revenue xxxxxxxxxxxxxxx93.5 M
Book Value Per Share xxxxxxxxxxxxxxx97.6
Net Operating Cash Flow xxxxxxxxxxxxxxx62.2 M
Net Profit Margin xxxxxxxxxxxxxxx47.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx48.46 %
Return on Invested Capital xxxxxxxxxxxxxxx47.50 %
Return on Assets xxxxxxxxxxxxxxx31.45 %
Return on Equity xxxxxxxxxxxxxxx48.46 %
Return on Total Capital xxxxxxxxxxxxxxx66.26 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx43.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

19/08/2022

3

Neutral

$55.00

-9.94%

Pro Medicus' FY22 release and subsequent presentation by management at the firm has triggered higher margin assumptions for Citi's modeling.

The broker observes the obvious: this business continues to grow "very strongly". There is, however, an elevated valuation that accompanies that growth, and this is keeping the rating on Neutral.

Citi's target price has increased to $55 from $46.

FORECAST
Citi forecasts a full year FY23 dividend of 26.10 cents and EPS of 52.20 cents.
Citi forecasts a full year FY24 dividend of 34.80 cents and EPS of 69.60 cents.

PME STOCK CHART